The following is an overview of
Ebola vaccines and serums under test and/or development. The speed with which
these have been created tells me the Ebola epidemic could have been stopped
with a much smaller effort if funds had been used several years ago.
Ebola vaccine development (photo NBC News)
From NBC News
Even though Ebola is burning out of control in West Africa, it’s not a huge potential market for a large pharmaceutical company to sink its teeth — and its assets — into developing. That leaves the U.S. government and small, niche biopharmaceutical companies.
“I don’t see why anybody except the U.S. government would get involved in developing these kinds of countermeasures,” said Dr. Sina Bavari of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Frederick, Maryland. “There is no market in it.”
More at
From the Guardian
“WHO aims for Ebola serum in weeks
and vaccine tests in Africa by January
Dr Marie Paule Kieny, an assistant
director general at the WHO, said the first tens of thousands of Ebola vaccines
could be distributed in the first months of the new year. Kieny acknowledged
there were many “ifs” remaining and “still a possibility that it [a vaccine]
will fail”. But she sketched out a much broader experiment than was imagined
only six months ago. “These are quite large trials,” she said.”
More at
From the BBC
Canada is to ship 800 vials of its
Ebola vaccine to the World Health Organization. The jab can completely protect
animals from a fatal dose of the Ebola virus. However, its safety and effectiveness
in humans is unknown. Trials began in the US this week and the WHO will conduct
further tests in Europe and Africa. The Public Health Agency of Canada said the
vaccine could be an "important tool in curbing the outbreak".
The recent Ebola outbreak - the
largest in history - has killed more than 4,500 people in West Africa. By
December, up to 10,000 people a week could be being infected by the virus, the
WHO says. There is no cure or proven vaccine, but a number of experimental
approaches are being rushed through.
More at
From Vox.com
Researchers have devoted lots of
time to building a vaccine that could stop the disease altogether — and
according to Daniel Bausch, a Tulane professor who researches Ebola and other
infectious diseases, they're making really significant progress.
Bausch says that the obstacle to
developing an Ebola vaccine isn't the science; researchers have actually made
really great strides in figuring out how to fight back against Ebola and the Marburg
virus, a similar disease.
"We now have a couple of
different vaccine platforms that have shown to be protective with non-human
primates," says Bausch, who has received awards for his work containing
disease outbreaks in Uganda. He is currently stationed in Lima, Peru, as the
director of the emerging infections department of Naval Medical Research Unit
6.
The problem, instead, is the
economics of drug development. Pharmaceutical companies have little incentive
to pour research and development dollars into curing a disease that surfaces
sporadically in low-income, African countries. They aren't likely to see a
large pay-off at the end — and could stand to lose money.
More at